MAIA Biotechnology, Inc.

Contributing Author

Recent Articles by MAIA Biotechnology, Inc.

Jun-18	MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University MAIA +6.06% GlobeNewswire
Jun-10	MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial MAIA GlobeNewswire
Jun-04	MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial MAIA GlobeNewswire
Jun-03	MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion MAIA +5.93% GlobeNewswire
Jun-02	MAIA Biotechnology Announces Open Market Purchases by CEO and Director MAIA GlobeNewswire
Jun-01	MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology MAIA -6.47% GlobeNewswire
Apr-16	MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer MAIA -6.34% GlobeNewswire
Apr-08	MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy MAIA GlobeNewswire
Mar-31	MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA +6.87% GlobeNewswire
Mar-04	MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock MAIA GlobeNewswire
Mar-02	MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock MAIA -27.05% GlobeNewswire
Mar-02	MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants MAIA -27.05% MAIA -8.41% GlobeNewswire
Feb-24	MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market MAIA +12.04% GlobeNewswire
Jan-20	MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum MAIA +26.44% GlobeNewswire
Dec-24	MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings MAIA +8.82% GlobeNewswire
Dec-16	MAIA Biotechnology Announces $1.51 Million Private Placement MAIA -8.89% MAIA -6.50% GlobeNewswire
Dec-11	MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates MAIA +18.84% MAIA -17.07% GlobeNewswire
Dec-11	MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer MAIA +18.84% GlobeNewswire
Dec-11	MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential MAIA +18.84% GlobeNewswire
Dec-10	MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach MAIA GlobeNewswire
Dec-01	MAIA Biotechnology Announces Open Market Purchases by CEO and Directors MAIA GlobeNewswire
Nov-21	MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 MAIA GlobeNewswire
Nov-20	MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation MAIA -5.33% GlobeNewswire
Oct-27	MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics MAIA GlobeNewswire
Oct-23	MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA +7.35% GlobeNewswire
Oct-13	MAIA Biotechnology Announces $736,600 Private Placement MAIA -6.37% MAIA GlobeNewswire
Oct-07	MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets MAIA GlobeNewswire
Sep-29	MAIA Biotechnology Announces $2.25 Million Private Placement MAIA GlobeNewswire
Sep-24	MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent MAIA GlobeNewswire
Sep-11	MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA +8.97% GlobeNewswire
Sep-05	MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer MAIA GlobeNewswire
Aug-27	MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells MAIA +7.14% GlobeNewswire
Aug-13	MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy MAIA GlobeNewswire

MAIA Biotechnology, Inc.

Recent Articles by MAIA Biotechnology, Inc.

Upgrade your Finviz experience